Oxford, UK, 21st October 2010, ProImmune Ltd., a leading provider of services for epitope discovery and immunogenicity risk assessment, announced today that its assay services for measuring cell mediated immune responses, including ELISpot assays, are now available in accordance with GLP and GCP.
Assays for measuring cellular immune responses help address key questions in the development of biological therapies. However, pharmaceutical companies often have difficulties integrating these assays into their preclinical and clinical development processes while complying with GLP and GCP. Outsourcing cellular assays to a dedicated facility working to GLP and GCP standards overcomes this problem, ensures data fully meet the requirements of regulatory submission and saves the cost and effort of setting up these time-consuming assays in-house.
Dr. Nikolai Schwabe, CEO of ProImmune, said: “Complying formally with GLP and GCP standards addresses an unmet need for many developers of novel therapies. It also demonstrates ProImmune’s commitment to supporting our customers’ requirement for understanding and characterizing immune response in all phases of pharmaceutical product development.”
About ProImmune - www.proimmune.com
ProImmune is a private biotechnology company that specializes in providing products and services for epitope discovery, immune monitoring and the design of biological drugs with reduced immunogenicity risk. ProImmune has a wide range of customers, including leading pharmaceutical and biotechnology companies, as well as clinical and academic research institutes throughout the world.
For more information, please contact
Dr Nikolai Schwabe, CEO
Tel: +44 (0) 870 042 7279
College Hill Life Sciences
Adam Michael and Jayne Crook
Tel: +44 (0)207 866 7862